Pharmacologic Management of Chronic Kidney Disease Due to Diabetes Mellitus Type 2
Webcast
1.5 Contact Hours Faculty
OVERVIEW
Pharmacologic Management of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 is organized by Nurse Practitioner Associates for Continuing Education (NPACE).
Expiration Date: December 31, 2025
Description:
Chronic kidney disease is a common complication of type 2 diabetes. Over the last ten years, evidence has accumulated that some glucose lowering agents are more effective than others at retarding progression of CKD in the setting of type 2 diabetes. This session will review these pharmacologic strategies for retarding progression.
Learning Objectives:
After taking part in this educational activity, participants should be better able to:
- Describe pharmacologic interventions that retard progression of CKD due to type 2 diabetes mellitus
- Recognize risk factors for hyperkalemia and apply management strategies
- Explain the relationship between cardiovascular disease and chronic kidney disease in type 2 diabetes
ACCREDITATION & CREDITS
Designation Statement
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.30 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
TARGET AUDIENCE
PhysicianNursingPharmacistEndocrinologistsNephrologistsClinical PharmacologySPECIALITIES
EndocrinologyNephrologyPharmacology
Quick Links